Core Insights - CytomX Therapeutics, Inc. granted options to purchase 130,000 shares of common stock at an exercise price of $1.96 on May 15, 2024, to two new employees [1][2] Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on oncology, developing conditionally activated, masked biologics aimed at localized tumor treatment [3] - The company utilizes its PROBODY® therapeutic platform to create safer and more effective cancer therapies [3] - CytomX's pipeline includes therapeutic candidates such as CX-904, CX-2051, and CX-801, targeting various cancer types through innovative mechanisms [3] Pipeline Details - CX-904 is a bispecific antibody targeting EGFR on tumor cells and CD3 on T cells, partnered with Amgen for global co-development [3] - CX-2051 is an ADC directed at EpCAM, with potential applications across multiple epithelial cancers, discovered in collaboration with Immunogen [3] - CX-801 is a masked interferon alpha-2b PROBODY® cytokine with potential in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading oncology companies including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3]

CytomX Therapeutics (NASDAQ:CTMX) stock is taking a beating on Thursday following a clinical trial update from the oncology-focused biopharmaceutical company.CytomX Therapeutics’ latest clinical trial update covers its Phase 1a study of CX-904, a cancer treatment in development. The company notes that the current results show a favorable safety profile and anti-cancer activity.However, diving into the data better explains why investors aren’t happy. Of the six pancreatic cancer patients able to be evaluated ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Results Conference Call May 8, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Wayne Chu - Chief Medical Officer Conference Call Participants Peter Lawson - Barclays Roger Song - Jefferies Joe Catanzaro - Piper Sandler Etzer Darout - BMO Capital Markets Anupam Rama - JPMorgan Mitchell Kapoor - H. C. Wainwright Operator Good day, and thank you for standing by. ...

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, including the execution of a clinical collaboration agreement with Merck to supply KEYTRUDA® (pembrolizumab ...

Exhibit 99.1 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T- cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, ...

As of the cutoff date, CX-904 demonstrated a favorable safety profile that supports administration and monitoring of enrolled patients in an outpatient setting. 1 There were no observed cases of cytokine release syndrome (CRS) of any grade in step-dosing cohorts as of the cutoff date. In non-step dosing cohorts, only Grade 1 CRS was observed in patients treated at the highest dose of 6 mg. Overall, the most common treatment-related adverse events (TRAEs) were rash, arthralgia, arthritis, pruritis, and vomit ...

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform -                   - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck squamous cell carcinoma - SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- CytomX Ther ...

CytomX Therapeutics (CTMX) shares soared 214.7% in the last trading session to close at $5.13. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 23.8% loss over the past four weeks.Last month, the company announced the dosing of the first patient in a phase I dose-escalation study evaluating its pipeline candidate, CX-2051, in patients with advanced solid tumors. This might have driven the share price rally.This biopharmaceutical c ...

CytomX (NASDAQ:CTMX) stock is rocketing higher on Wednesday after the company provided investors with an update for its upcoming earnings report.The oncology-focused biopharmaceutical company told traders that it will release its earnings report for the first quarter of 2024 when markets close on May 8, 2024. It will also host a conference call that same day starting at 5:00 p.m. Eastern Time.Investors will want to keep an eye on EPS and revenue as two important metrics in this earnings report. Wall Street ...

SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced the first patient has been dosed in a Phase 1 dose escalation study (NCT06265688) of CX-2051 in patients with advanced solid tumors. CX-2051 is a masked PROBODY® antibody drug conjugate (ADC) directed toward epithelial cell adhesion molecule (EpCAM), a cell-surface target that is highly expressed across many cancer typ ...